Core outcome set for lung cancer
This is a standardized set of outcomes that matter most to lung cancer patients and healthcare providers. It includes patient-reported experiences, quality of life, symptoms, and clinical data to help measure the true impact of treatments and improve care across Europe.
At a glance
Use when
Designing clinical trials, monitoring routine care quality, implementing value-based healthcare programs, or comparing outcomes across institutions in lung cancer.
Avoid when
When only narrow, specific endpoints are needed (e.g., single biomarker studies); when resources for collecting patient-reported data are unavailable.
Inputs
Literature review findings, expert opinion, patient input, Delphi survey responses from multidisciplinary stakeholders.
Outputs
A standardized core outcome set for lung cancer comprising 64 outcomes across case-mix, patient-reported, and clinical domains.
How it works
Developed by the European Health Outcomes Observatory (H2O) initiative through a Delphi study involving 126 participants (patients, healthcare professionals, industry, and regulators), this core outcome set (COS) for lung cancer was derived from a preliminary list of 102 outcomes, reduced to 64 through consensus (≥70% scoring as 'highly relevant'). The final COS comprises 27 case-mix factors, 25 patient-reported outcomes (PROs) related to health-related quality of life (HRQoL), and 12 clinical outcomes. It expands upon the 2016 ICHOM lung cancer set by including additional PRO symptoms such as insomnia, nausea, vomiting, anxiety, depression, and gastrointestinal issues. The COS integrates clinician- and patient-reported measures for value-based healthcare implementation.
- Project
- H2O
- Funding
- IMI
- Project status
- Ongoing
- HTA domains
- Clinical Effectiveness, Patient and Social Aspects
- Technology
- Non-specific
- Assumptions
- That patient-centered outcomes improve healthcare value; that consensus methods can identify universally relevant outcomes; that standardized measurement enables cross-institutional comparison.
- Strengths
- Incorporates broad international, multidisciplinary, and patient input; uses rigorous Delphi methodology; expands on prior sets with additional symptoms; supports value-based healthcare; designed for pan-European implementation.
- Limitations
- May require adaptation for non-European contexts; implementation depends on infrastructure for collecting patient-reported outcomes; not all outcomes may be relevant for every treatment or stage of disease.
- Geographic & clinical scope
- Lung Cancer
- Also known as
- H2O Lung Cancer Core Outcome Set, Lung Cancer COS, European Core Outcome Set for Lung Cancer
Questions this answers
- › What outcomes should be measured to reflect what matters most to lung cancer patients?
- › How can lung cancer treatment results be compared consistently across different healthcare settings?
- › Which patient-reported symptoms should be routinely monitored in lung cancer care?
- › What data are needed to support value-based healthcare in lung cancer?
- › How does this set improve upon previous outcome recommendations like ICHOM's 2016 set?
- › Can this outcome set help standardize quality of care across Europe?
Related methods
Similar by meaning
Beta record. Generated from the primary source via AI extraction and independent audit, pending final human review.